Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — August 2020

Planlagt Fastgjort Låst Flyttet Genmab
1.0k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #165

    i think it is a bit more then that , "Collectively, these findings demonstrate that amivantamab Fc-interaction with macrophages and
    monocytes induces trogocytosis which is a dominant mechanism underlying the anti-tumor

    efficacy of amivantamab."

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #166

      "Previously, trogocytosis was described as a mechanism of resistance for antibodies such as

      However, in this study, we demonstrated a novel role for

      trogocytosis (ADCT) as a crucial inducer of Fc-dependent receptor downmodulation and antitumor
      effects.

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #167

        In addition to targeting a
        conserved region of an oncogenic receptor, which broadens the targeted population, the
        selectivity of bispecific antibodies like amivantamab, could offer a reduced potential for toxicity,
        making combination therapy with additional agents better tolerated.

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #168

          Our findings demonstrate
          that the Fc-dependent activity of amivantamab is driven by macrophage- and monocyte-mediated
          trogocytosis, a dominant mechanism of antibody-directed receptor downregulation and tumor
          cell killing. These findings highlight the potential of trogocytosis as therapeutic modality but also
          provide insights to guide patient selection and combination strategies for amivantamab."

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #169

            BNT311 – BioNTech expects to provide a data update in 2H 2020, which will include dose-escalation data from the Phase 1/2 trial in multiple solid tumors for GEN1042/BNT311 (PD-L1x4-1BB). The program is partnered with Genmab. -as previously stated

            1 Reply Last reply
            0
            • B Offline
              B Offline
              BioShare
              wrote on sidst redigeret af
              #170

              Om­sæt­nin­gen ven­tes at syv­dob­les - Børsen. https://borsen.dk/nyheder/virksomheder/i-genmab-regnskab-tikker-milliarder-fra-abbvie-aftale-ind-omsaetningen-ventes-at-syvdobles

              1 Reply Last reply
              0
              • K Offline
                K Offline
                Klarussen
                wrote on sidst redigeret af
                #171

                SEB sænker anbefaling til SÆLG:
                https://www.euroinvestor.dk/nyheder/seb-om-genmab-saenker-anbefaling-til-saelg

                1 Reply Last reply
                0
                • K Offline
                  K Offline
                  Klarussen
                  wrote on sidst redigeret af
                  #172

                  Nu sv.t. kurs 2286 i US

                  1 Reply Last reply
                  0
                  • Legolas23L Offline
                    Legolas23L Offline
                    Legolas23
                    wrote on sidst redigeret af
                    #173

                    Du kan ikke bruge den amerikanske add til noget i forhold til næste dags danske åbningskurs. Casen og regnskabet i morgen bør have al opmærksomhed.

                    1 Reply Last reply
                    0
                    • B Offline
                      B Offline
                      bikube
                      wrote on sidst redigeret af
                      #174

                      Horizon faldt 5,5%, det var da en røvfuld.

                      1 Reply Last reply
                      0
                      • Helge_LarsenPI-redaktørH Offline
                        Helge_LarsenPI-redaktørH Offline
                        Helge_LarsenPI-redaktør
                        wrote on sidst redigeret af
                        #175

                        God morgen. 🙂

                        1 Reply Last reply
                        0
                        • Helge_LarsenPI-redaktørH Offline
                          Helge_LarsenPI-redaktørH Offline
                          Helge_LarsenPI-redaktør
                          wrote on sidst redigeret af
                          #176

                          Husk at NBI index finder man i menulinjen under marked.

                          1 Reply Last reply
                          0
                          • Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktør
                            wrote on sidst redigeret af
                            #177

                            Her ligger også flere andre nyttige features.

                            1 Reply Last reply
                            0
                            • B Offline
                              B Offline
                              bibob
                              wrote on sidst redigeret af
                              #178

                              God morgen. 🙂

                              1 Reply Last reply
                              0
                              • T Offline
                                T Offline
                                transalp
                                wrote on sidst redigeret af
                                #179

                                Go morgen.. 🙂

                                1 Reply Last reply
                                0
                                • M Offline
                                  M Offline
                                  Mogan
                                  wrote on sidst redigeret af
                                  #180

                                  God Morgen 🙂

                                  1 Reply Last reply
                                  0
                                  • J Offline
                                    J Offline
                                    JKY_VH
                                    wrote on sidst redigeret af
                                    #181

                                    Novod løfter til 1872 fra 1811 og stadig hold.

                                    1 Reply Last reply
                                    0
                                    • J Offline
                                      J Offline
                                      JKY_VH
                                      wrote on sidst redigeret af
                                      #182

                                      ja sådan er det jo

                                      1 Reply Last reply
                                      0
                                      • S Offline
                                        S Offline
                                        Stroka
                                        wrote on sidst redigeret af
                                        #183

                                        SEB:

                                        • I øjeblikket virker det som om, at selskabet ikke kan noget forkert. Imidlertid mener vi, at aktien er mere end fuldt prissat, og vi sænker vores anbefaling til sælg, hedder det i notatet.

                                        Det nye kursmål indikerer et negativt potentiale i biotekaktien på 15 pct. i forhold til lukkekursen tirsdag i 2319 kr.

                                        SEB har i sine estimater indregnet et væsentligt højere bidrag fra øjenmidlet Tepezza, efter at selskabet bag markedsføringen Horizon har løftet sine forventninger til salget.

                                        1 Reply Last reply
                                        0
                                        • Helge_LarsenPI-redaktørH Offline
                                          Helge_LarsenPI-redaktørH Offline
                                          Helge_LarsenPI-redaktør
                                          wrote on sidst redigeret af
                                          #184

                                          SEB har hidtil haft en neutral anbefaling af aktien i Genmab siden januar 2019, da kursen på aktien lå i 1084 kr.

                                          /ritzau/FINANS

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger